Asset Details
Do you wish to reserve the book?
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial
Do you wish to request the book?
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial
2021
Overview
Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces cardiovascular death and worsening heart failure in patients with chronic heart failure and reduced ejection fraction. Early initiation during an acute heart failure (AHF) hospitalization may facilitate decongestion, improve natriuresis, and facilitate safe transition to a beneficial outpatient therapy for both diabetes and heart failure.
The objective is to assess the efficacy and safety of initiating dapagliflozin within the first 24 hours of hospitalization in patients with AHF compared to usual care.
DICTATE-AHF is a prospective, multicenter, open-label, randomized trial enrolling a planned 240 patients in the United States. Patients with type 2 diabetes hospitalized with hypervolemic AHF and an estimated glomerular filtration rate of at least 30 mL/min/1.73m2 are eligible for participation. Patients are randomly assigned 1:1 to dapagliflozin 10 mg once daily or structured usual care until day 5 or hospital discharge. Both treatment arms receive protocolized diuretic and insulin therapies. The primary endpoint is diuretic response expressed as the cumulative change in weight per cumulative loop diuretic dose in 40 mg intravenous furosemide equivalents. Secondary and exploratory endpoints include inpatient worsening AHF, 30-day hospital readmission for AHF or diabetic reasons, change in NT-proBNP, and measures of natriuresis. Safety endpoints include the incidence of hyper/hypoglycemia, ketoacidosis, worsening kidney function, hypovolemic hypotension, and inpatient mortality.
The DICTATE-AHF trial will establish the efficacy and safety of early initiation of dapagliflozin during AHF across both AHF and diabetic outcomes in patients with diabetes.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Benzhydryl Compounds - therapeutic use
/ Diabetes
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - metabolism
/ Dosage
/ Glucose
/ Glucosides - therapeutic use
/ Heart Failure - complications
/ Heart Failure - drug therapy
/ Humans
/ Hypoglycemic Agents - therapeutic use
/ Insulin
/ Natriuretic Peptide, Brain - metabolism
/ Patients
/ Peptide Fragments - metabolism
/ Randomized Controlled Trials as Topic
/ Renal Insufficiency, Chronic - complications
/ Safety
/ Sodium Potassium Chloride Symporter Inhibitors - therapeutic use
/ Sodium-glucose cotransporter
/ Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
/ Urine
